Replaces Prod. #: ALX-350-069
Plant alkaloid that arrests the cell cycle in G2/M phase by blocking mitotic spindle formation. Depolymerizes microtubules and blocks binding of tubulin to microtubule proteins. Causes aberrant tubulin polymerization. Induces apoptosis. Triggers Raf-1 activation, phosphorylation of Bcl-2 family proteins and induction of p53 expression. Cancer chemotherapeutic agent. Posttranscriptionally downregulates HIF-1α expression.
Product Details
| Alternative Name: | VCR . sulfate, Leukocristine . sulfate |
| |
| Formula: | C46H56N4O10 . H2SO4 |
| |
| MW: | 825.0 . 98.1 |
| |
| CAS: | 2068-78-2 |
| |
| MI: | 14: 9986 |
| |
| RTECS: | OH6340000 |
| |
| Purity: | ≥98% TLC |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in water (25mg/ml) or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Handling: | Protect from light and moisture. |
| |
| Technical Info/Product Notes: | Note: Product is not sterile. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity: J.H. Park, et al.; In Vivo
36, 694 (2022),
Abstract;
Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition: J.S. Lim, et al.; Anticancer Res.
36, 5063 (2016),
Application(s): Cell Treatment,
Abstract;
Full Text
Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition: A.R. Choi, et al.; Eur. J. Pharmacol.
764, 63 (2015),
Application(s): Cell Culture,
Abstract;
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF: N.J. Mabjeesh, et al.; Cancer Cell
3, 363 (2003),
Abstract;
Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro: J.A. Vilpo, et al.; Eur. J. Haematol.
65, 370 (2000),
Abstract;
Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells of children with acute lymphoblastic leukaemia (ALL): E. Groninger, et al.; Br. J. Haematol.
111, 875 (2000),
Abstract;
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review: L.G. Wang, et al.; Cancer Chemother. Pharmacol.
44, 355 (1999), (Review),
Abstract;
Bcl-xL is phosphorylated in malignant cells following microtubule disruption: M.S. Poruchynsky, et al.; Cancer Res.
58, 3331 (1998),
Abstract;
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle: A. Jordan, et al.; Med. Res. Rev.
18, 259 (1998),
Abstract;
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death: M.V. Blagosklonny, et al.; Cancer Res.
57, 130 (1997),
Abstract;
Antimitotic natural products and their interactions with tubulin: E. Hamel; Med. Res. Rev.
16, 207 (1996),
Abstract;
Bcl-2 interrupts the ceramide-mediated pathway of cell death: J. Zhang, et al.; PNAS
93, 5325 (1996),
Abstract;
Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine: S. Lobert, et al.; Biochemistry
35, 6806 (1996),
Abstract;
Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins [published erratum appears in BBRC 190, 1180 (1993)]: Y. Li, et al.; BBRC
187, 722 (1992),
Abstract;
Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line: B.V. Harmon, et al.; Cell Prolif.
25, 523 (1992),
Abstract;
Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules: R.H. Himes; Pharmacol. Ther.
51, 257 (1991),
Abstract;
Related Products
